Literature DB >> 9086136

Anti-interleukin-6 antibodies inhibit herpes simplex virus reactivation.

J D Kriesel1, B M Gebhardt, J M Hill, S A Maulden, I P Hwang, T E Clinch, X Cao, S L Spruance, B A Araneo.   

Abstract

Herpes simplex viruses (HSVs) infect epithelial cells, become localized in neurons, and can reactivate in response to a variety of stimuli, including ultraviolet light and hyperthermia. The sequence of gene activation during viral replication is known, but the molecular linkage between exogenous stimuli and HSV reactivation has not been determined. It was hypothesized that interleukin (IL)-6 acts as a signal between exogenous stimuli and neurons, stimulating HSV reactivation from latency. Mouse corneas were infected with HSV-1, and ocular reactivation was induced 5-7 weeks later by thermal stress or corneal exposure to ultraviolet light. Anti-IL-6 monoclonal antibodies were administered to the latently infected mice 8-12 h before the reactivation stimulus. Treatment with anti-IL-6 antibodies resulted in significantly lower frequencies of ocular reactivation compared with those in mice treated with a control immunoglobulin. These results support the hypothesis that IL-6 plays a role in HSV reactivation from latency.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9086136     DOI: 10.1086/513977

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  Molecular diagnosis of herpes simplex virus infections in the central nervous system.

Authors:  Y W Tang; P S Mitchell; M J Espy; T F Smith; D H Persing
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Experimental human cytomegalovirus latency in CD14+ monocytes.

Authors:  Danna Hargett; Thomas E Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

3.  Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells.

Authors:  Ayuko Sato; Melissa M Linehan; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-03       Impact factor: 11.205

Review 4.  Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Authors:  Lena J Al-Dujaili; Patrick P Clerkin; Christian Clement; Harris E McFerrin; Partha S Bhattacharjee; Emily D Varnell; Herbert E Kaufman; James M Hill
Journal:  Future Microbiol       Date:  2011-08       Impact factor: 3.165

5.  Tumor necrosis factor alpha and interleukin-6 facilitate corneal lymphangiogenesis in response to herpes simplex virus 1 infection.

Authors:  Katie M Bryant-Hudson; Hem R Gurung; Min Zheng; Daniel J J Carr
Journal:  J Virol       Date:  2014-10-08       Impact factor: 5.103

6.  Molecular evidence and clinical significance of herpesvirus coinfection in the central nervous system.

Authors:  Y W Tang; M J Espy; D H Persing; T F Smith
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

7.  Lack of interleukin-6 (IL-6) enhances susceptibility to infection but does not alter latency or reactivation of herpes simplex virus type 1 in IL-6 knockout mice.

Authors:  R A LeBlanc; L Pesnicak; E S Cabral; M Godleski; S E Straus
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

8.  Delivery of Interferon-gamma by an adenovirus vector blocks herpes simplex virus Type 1 reactivation in vitro and in vivo independent of RNase L and double-stranded RNA-dependent protein kinase pathways.

Authors:  Daniel J J Carr; Bobbie A Austin; William P Halford; Patrick M Stuart
Journal:  J Neuroimmunol       Date:  2008-11-29       Impact factor: 3.478

9.  Role of activating transcription factor 3 in the synthesis of latency-associated transcript and maintenance of herpes simplex virus 1 in latent state in ganglia.

Authors:  Minfeng Shu; Te Du; Grace Zhou; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

10.  STAT1 binds to the herpes simplex virus type 1 latency-associated transcript promoter.

Authors:  John D Kriesel; Brandt B Jones; Kimberly M Dahms; S L Spruance
Journal:  J Neurovirol       Date:  2004-02       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.